| BIOCRYST PHARMACEUTICALS |
| USA |
| Gesundheit |
| US09058V1035 / 896047 |
| BO1 (Frankfurt) / BCRX (NASDAQ) |
| FRA:BO1, ETR:BO1, BO1:GR, NASDAQ:BCRX |
| - |
| https://www.biocryst.com/ |
|
BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, ..
>Volltext.. |
| 2038.01 Mio. EUR |
| 2210.25 Mio. EUR |
| 757.88 Mio. EUR |
| 296.61 Mio. EUR |
| 228.59 Mio. EUR |
| 1.08 EUR |
| 413.52 Mio. EUR |
| 77.91 Mio. EUR |
| 285.78 Mio. EUR |
| 1.4 |
| 71.08% |
| - |
| - |
| - |
| - |
| BIOCRYST |
| 05.04.26 |
|